OUR PRODUCTS
Our Pipeline
We challenge ourselves to rethink the way medicines are developed,
and
are investing now to bring more value to patients in the future.
We strive for constant innovation and we are putting our passion and expertise to work in new areas including hematology, gastroenterology and endocrinology.
SB12
Biosimilar candidate
- Molecule Eculizumab
- Reference Biologic Solirisii
- Therapeutic Area Hematology
SB15i
Biosimilar candidate
- Molecule Aflibercept
- Reference Biologic Eyleaiii
- Therapeutic Area Ophthalmology
SB16
Biosimilar candidate
- Molecule Denosumab
- Reference Biologic Proliaiv
- Therapeutic Area Endocrinology
SB17
Biosimilar candidate
- Molecule Ustekinumab
- Reference Biologic Stelarav
- Therapeutic Area immunology
SB26
Novel biologic
- Molecule Ulinastatin-Fc
Fusion Protein - Therapeutic Area Gastroenterology
*Pipeline last updated Jul 2022
- iPhase I clinical trial was waived for SB15
- iiSoliris is a registered trademark of Alexion
- iiiEylea is a registered trademark of Regeneron
- ivProlia is a registered trademark of Amgen
- vStelara is a registered trademark of Janssen
